Main Conference Day 1 (28th April 2026) - CET/CEST (Cent Europe Summer, GMT+2)
- Felix Wittkopp - Director of Purification Development Gene Therapy - Gene Therapy Technical Research & Development, Roche, Germany
- Frank Agbogbo - Vice President, Forge Biologics, USA
AAV vector manufacturing remains one of the most significant bottlenecks in gene therapy. Traditional cell-based production systems are slow, variable, and resource-intensive - relying on fragile biological processes developed decades ago. These inefficiencies not only hinder progress toward larger patient populations and new indications but also limit innovation in rare and ultra-rare diseases, where manufacturing costs can outweigh any commercial incentive to develop therapies. The result is a field constrained by biology, cost, and scale. Fuse Vectors is pioneering a fundamentally new approach: a cell-free, enzymatic system that assembles high-quality AAV vectors in hours, not weeks. This breakthrough forms the foundation of the Fuse Platform, comprising three integrated components. Fuse Cell-Free Technology eliminates the need for producer cells and enables direct, programmable AAV assembly. The Fuse Foundry leverages this speed and precision to allow partners and customers to rapidly prototype and select optimal vector candidates. Fuse Scale-Up, advancing toward GMP, extends these processes seamlessly to manufacturing scale: offering a consistent, economically viable route from discovery to clinic. We will share quantitative data demonstrating the efficiency, fidelity, and scalability of cell-free AAV production—achieving >99% full capsids in a single, 4-hour process and yields exceeding cell-based systems by more than tenfold. New in vivo benchmarking results, comparing cell-free and HEK-based AAV in disease-relevant models, will be presented for the first time. Together, these findings illustrate how removing biological constraints delivers step-change improvements in quality, reproducibility, and cost - redefining the path toward scalable and accessible gene therapy manufacturing.
- Jordan Turnbull - Co-Founder, Co-CEO, CSO, Fuse Vectors
- Hollie Bartley - Director, Process Development, Resolution Therapeutics
- Pablo Mancheño Corvo - Associate Scientific Director, Takeda, Spain
Have a Solution for This Challenge?
This session is your platform to demonstrate leadership and technical expertise. Present your data, case studies, and innovative solutions to a targeted audience of senior scientists and engineers looking to solve hurdles in their production processes.
To learn more about sponsoring this session, contact us at Partners@informaconnectls.com
